

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

July 14, 2021

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for April 21, 2021 meeting
- IV. Review of draft meeting summary for April 21, 2021 meeting
- V. Secretary's report
- VI. Old Business
 - A. United Healthcare clinical criteria not met denials report
 - B. Horizon examples of incomplete information denials resolution
- VII. New Business
 - A. Addendum for direct acting antiretrovirals (DAAs) for HCV protocol
 - B. Addendum for Dupixent® (dupilumab) protocol
 - C. Addendum for Vyondys® (golodirsen) protocol
 - D. Addendum for Epidiolex® (cannabidiol) protocol
 - E. Addendum for Cablivi® (caplacizumab) protocol
 - F. Proposed protocol for Cabenuva® (cabotegravir/rilpivirine) injectable
 - G. Proposed protocol for biologic response modifier products used in plaque psoriasis
 - H. Proposed protocol for Lumizyme® (alglucosidase alfa)
 - I. Proposed protocol for Myalept® (metreleptin)
- VIII. A. Informational Highlights/Reports
 - 1. DXC Technology/NJ HMO 1st Quarter 2021 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
 - (b) Antiviral drugs by amount paid

B. Medication information:

1. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.

3. New Jersey COVID-19 Information Hub (continuously updated)

<https://covid19.nj.gov/>

4. Monoclonal Antibody Therapy for COVID-19 in New Jersey

https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMImL6v7fD28AIVi8CGCh3jjQQVEAAYASAAEgLggvD_BwE

5. NEW: Sotrovimab – Emergency Use Authorization (EUA) granted for the Treatment of COVID-19

<https://www.sotrovimab.com/hcp/>

IX. Referenced Materials:

A. Protocol for DAAs for HCV (last updated and approved July 2018)

B. Dupixent® (dupilumab) protocol (last updated and approved July 2020)

C. Vyondys® (golodirsen) protocol (Approved 2020)

D. Epidiolex® (cannabidiol) protocol (approved January 2019)

E. Cablivi® (caplacizumab) protocol (approved October 2019)